• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

    10/28/24 7:00:00 AM ET
    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Industrial Specialties
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ISRG alert in real time by email

    SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner.

    Sonder Capital

    Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered the use of person-generated health data and connected devices in decentralized research and large-scale health programs. Prior to Evidation, Kilpatrick held leadership roles in medical device and molecular diagnostic companies, including multiple roles at Guidant Corporation such as Research Fellow, Director of Research and Technology Development, and Director of New Ventures, prior to its acquisition by Boston Scientific. She is the co-Founder of MedtechWomen and the MedtechVision Conference, held annually in Silicon Valley and currently serves on the Board of Directors at Sleep Number (NASDAQ:SNBR), NextGen Jane, and Sutter Health, one of the largest and most innovative healthcare systems in the US providing care to millions throughout California.

    Kilpatrick's background in medical devices coupled with her expertise in digital health technology will strengthen the Sonder team's ability to navigate and identify future investments in the medtech sector as it rapidly evolves to integrate multi-modal health data and AI.

    "I'm excited to join the Sonder team and be a part of creating what's next in medtech," said Kilpatrick. "There is no doubt that the sector has driven better patient outcomes for decades. But I believe medtech is entering a new era where novel technologies will drive entirely new standards of care and transform both the clinician and patient experience in ways we are just beginning to imagine."

    "We couldn't be more excited to welcome Deb to the Sonder team," said Kate Garrett, Managing Partner of Sonder Capital. "The future of the medtech industry will become a convergence of big data, AI and connected devices, creating unprecedented opportunities to improve healthcare. With a career deeply rooted in all of these areas, Deb brings unparalleled expertise to our team. Beyond that, Deb has been a champion of women leaders in the healthcare sector her entire career, something I and thousands of others have benefitted from. We are thrilled to be working side by side with her."

    About Sonder Capital

    Sonder's team of veteran investors, innovators, founder-operators, and company builders is known not only for their individual achievements, but also for their collective success in creating, funding, and leading private and public companies that have transformed healthcare for millions of patients globally — including Intuitive Surgical (NASDAQ:ISRG), Shockwave Medical (NASDAQ:SWAV), Procept Biorobotics (NASDAQ:PRCT), Auris Health, and Reflexion Medical, among others. Sonder's extensive network of limited partners is global and includes industry leaders, high-net-worth individuals, and leading family offices focused on investing in game-changing healthcare technologies. Sonder Capital was co-founded in 2019 by healthcare luminaries Jay Watkins and Fred Moll, M.D

    Contacts

    Marisa Meehan, Sonder Capital

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/deborah-kilpatrick-joins-sonder-capital-as-its-newest-venture-partner-302288301.html

    SOURCE Sonder Capital

    Get the next $ISRG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • Who has been appointed as the new Venture Partner at Sonder Capital?

      Deborah Kilpatrick has joined Sonder Capital as a Venture Partner, bringing extensive experience in healthcare technology and leadership roles in the medtech sector.

    • What was Deborah Kilpatrick's previous role before joining Sonder Capital?

      Kilpatrick was previously the CEO of Evidation Health, where she led efforts in utilizing person-generated health data and connected devices for research and health programs.

    • What is Deborah Kilpatrick's educational background?

      Kilpatrick holds a Ph.D. in mechanical engineering with a focus on bioengineering from Georgia Tech and has been involved in various leadership roles in medical device companies, including Guidant Corporation.

    • Why is Deborah Kilpatrick's addition significant for Sonder Capital?

      Joining Sonder Capital enhances their investment capabilities in the rapidly evolving medtech sector, especially in areas integrating multi-modal health data and AI.

    • What vision did Deborah Kilpatrick express about the future of the medtech sector?

      Kilpatrick emphasized that medtech is entering a new era where innovative technologies will set new standards of care and significantly enhance patient and clinician experiences.

    Recent Analyst Ratings for
    $ISRG
    $PRCT
    $SNBR
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Intuitive Surgical Inc.
    $ISRG
    7/23/2025Buy → Hold
    Erste Group
    PROCEPT BioRobotics Corporation
    $PRCT
    7/9/2025$70.00Overweight
    Stephens
    PROCEPT BioRobotics Corporation
    $PRCT
    7/7/2025Perform
    Oppenheimer
    Intuitive Surgical Inc.
    $ISRG
    6/9/2025$440.00Hold → Sell
    Deutsche Bank
    Intuitive Surgical Inc.
    $ISRG
    6/5/2025Hold → Buy
    Erste Group
    PROCEPT BioRobotics Corporation
    $PRCT
    12/2/2024$105.00Overweight
    Morgan Stanley
    Intuitive Surgical Inc.
    $ISRG
    12/2/2024$522.00 → $650.00Equal-Weight → Overweight
    Morgan Stanley
    PROCEPT BioRobotics Corporation
    $PRCT
    11/14/2024$95.00Hold
    Jefferies
    More analyst ratings

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moll Frederic H bought $785,138 worth of shares (20,000 units at $39.26), increasing direct ownership by 2% to 863,159 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:18:26 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Interim CFO Ryder Robert P bought $102,160 worth of shares (15,000 units at $6.81) (SEC Form 4)

    4 - Sleep Number Corp (0000827187) (Issuer)

    8/4/25 4:05:05 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Director Eyler Phillip bought $74,942 worth of shares (8,300 units at $9.03), increasing direct ownership by 65% to 20,972 units (SEC Form 4)

    4 - Sleep Number Corp (0000827187) (Issuer)

    5/14/25 4:01:01 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Financials

    Live finance-specific insights

    View All

    PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2025. Recent Highlights Total revenue of $79.2 million for the second quarter of 2025, an increase of 48% compared to the prior year period in 2024U.S. handpiece and consumables revenue of $43.1 million for the second quarter of 2025, an increase of 58% compared to the prior year period in 2024Sold 51 robotic systems in the U.S. in the second quarter of 2025U.S. system and rental revenue o

    8/6/25 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Sleep Number Announces Second Quarter 2025 Results

    Cost Savings to Exceed Initial Targets While Maintaining Compliance with Debt Covenants Company Implementing Significant Changes to Business with Enhanced Marketing, Product Initiatives Reported net sales of $328 million, down 19.7% compared with the second quarter of 2024 Delivered gross profit margin of 59.1%, flat versus the prior year Reduced second quarter operating expenses by $48 million, or 21%, year-over-year, before restructuring and other non-recurring costs Reported net loss of $25 million, inclusive of a $13 million adjustment to valuation of deferred tax assets, compared to a net loss of $5 million for the same period last year Delivered adjusted EBITDA of $24

    7/30/25 8:00:00 AM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Intuitive Announces Second Quarter Earnings

    SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2025. Q2 Highlights Worldwide da Vinci procedures grew approximately 17% compared with the second quarter of 2024.The Company placed 395 da Vinci surgical systems, compared with 341 in the second quarter of 2024. The second quarter 2025 da Vinci surgical system placements included 180 da Vinci 5 systems, compared with 70 in the second quarter of 2024.The Company grew its da Vinci surgical system installed base to 10,488 systems as of

    7/22/25 4:05:00 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intuitive Surgical downgraded by Erste Group

    Erste Group downgraded Intuitive Surgical from Buy to Hold

    7/23/25 8:54:24 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    Stephens initiated coverage on PROCEPT BioRobotics with a new price target

    Stephens initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $70.00

    7/9/25 8:44:45 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Oppenheimer initiated coverage on PROCEPT BioRobotics

    Oppenheimer initiated coverage of PROCEPT BioRobotics with a rating of Perform

    7/7/25 8:02:36 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    SEC Filings

    View All

    SEC Form 10-Q filed by PROCEPT BioRobotics Corporation

    10-Q - PROCEPT BioRobotics Corp (0001588978) (Filer)

    8/7/25 4:39:41 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)

    8/6/25 4:09:18 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Sleep Number Corporation

    S-8 - Sleep Number Corp (0000827187) (Filer)

    7/31/25 4:07:25 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Strategic Advisor Lee Francis K covered exercise/tax liability with 2,671 shares, decreasing direct ownership by 12% to 18,874 units (SEC Form 4)

    4 - Sleep Number Corp (0000827187) (Issuer)

    8/19/25 12:11:52 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Director Desai Antal Rohit exercised 26,749 shares at a strike of $1.33, increasing direct ownership by 318% to 35,152 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/15/25 4:53:14 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Director Moll Frederic H bought $785,138 worth of shares (20,000 units at $39.26), increasing direct ownership by 2% to 863,159 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:18:26 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2025. Recent Highlights Total revenue of $79.2 million for the second quarter of 2025, an increase of 48% compared to the prior year period in 2024U.S. handpiece and consumables revenue of $43.1 million for the second quarter of 2025, an increase of 58% compared to the prior year period in 2024Sold 51 robotic systems in the U.S. in the second quarter of 2025U.S. system and rental revenue o

    8/6/25 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Sleep Number Announces Second Quarter 2025 Results

    Cost Savings to Exceed Initial Targets While Maintaining Compliance with Debt Covenants Company Implementing Significant Changes to Business with Enhanced Marketing, Product Initiatives Reported net sales of $328 million, down 19.7% compared with the second quarter of 2024 Delivered gross profit margin of 59.1%, flat versus the prior year Reduced second quarter operating expenses by $48 million, or 21%, year-over-year, before restructuring and other non-recurring costs Reported net loss of $25 million, inclusive of a $13 million adjustment to valuation of deferred tax assets, compared to a net loss of $5 million for the same period last year Delivered adjusted EBITDA of $24

    7/30/25 8:00:00 AM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO

    Larry L. Wood to join PROCEPT BioRobotics effective September 2, 2025Company confirms strong underlying business trends and pre-announces 2Q25 revenue of approximately $79.2 million, representing annual growth of 48% SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) ("the Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that Larry L. Wood will join the Company as president and CEO effective September 2, 2025. Dr. Reza Zadno will retire as president, CEO, and director effective September 1, 2025. Since 2020, Dr. Zadno has led the Company through significant growth

    7/24/25 6:00:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    30 years of Innovation and Impact: Dan Larson's Inspiring Story

    SUNNYVALE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- When Seattle resident Dan Larson was diagnosed with lung cancer in 2023, his only exposure to robotic technology was through his work as a quality engineer at Boeing. He could never have imagined that robotic technology made by Intuitive, the pioneer of robotic-assisted surgery, would one day play a pivotal role in his health care. Having experienced the loss of his father to lung cancer, Dan was determined to overcome his own diagnosis and enjoy his retirement with his family. Under the care of clinicians at MultiCare Tacoma General Hospital in Washington, Dan underwent two robotic lung biopsies with the Ion Endoluminal System, Intuit

    5/27/25 9:15:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    Sleep Number Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    Sleep Number Corporation (NASDAQ:SNBR) today announced that it granted equity awards on May 15, 2025, as a material inducement to the employment of the company's newly-hired Executive Vice President and Chief Marketing Officer, Amber Minson. In connection with the appointment of Minson as Executive Vice President and Chief Marketing Officer effective May 5, 2025, Sleep Number granted Minson employment inducement awards consisting of: (i) 21,724 shares in a performance stock unit award vesting on the third anniversary of the date of grant with the number of shares to be earned based on actual company performance for fiscal years 2025 to 2027 and the company's relative total shareholder retu

    5/16/25 9:01:00 AM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Intuitive Announces CEO Transition Effective July 1, 2025

    President Dave Rosa promoted to CEOCurrent CEO Gary Guthart to become executive chair of Intuitive's boardCurrent Board Chair Craig Barratt to become lead independent director SUNNYVALE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the promotion of President Dave Rosa to chief executive officer, effective July 1, 2025. At that time, current CEO Gary Guthart will become the executive chair of Intuitive's board of directors, and current Board Chair Craig Barratt will become lead independent director. Guthart will work closely with Rosa to support a smooth t

    5/15/25 9:05:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Sleep Number Corporation

    SC 13D/A - Sleep Number Corp (0000827187) (Subject)

    12/2/24 5:07:30 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Sleep Number Corporation

    SC 13D/A - Sleep Number Corp (0000827187) (Subject)

    11/25/24 6:54:27 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/14/24 1:28:32 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care